Position in SCLX
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$6
-$6 QoQ
Shares Held
1
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in SCLX Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Mar 31, 2026Arax Advisory Partners holds $77,931,466 across 17 Drug Manufacturers - General names. SCLX ranks #17 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MRK |
Merck & Co., Inc.
|
303,856 | $36,550,838 | |
| 2 | ABBV |
AbbVie Inc.
|
48,857 | $10,625,908 | |
| 3 | JNJ |
Johnson & Johnson
|
41,381 | $10,115,171 | |
| 4 | LLY |
ELI LILLY & Co
|
6,998 | $6,436,550 | |
| 5 | BMY |
Bristol Myers Squibb Co
|
73,108 | $4,434,000 | |
| 6 | PFE |
Pfizer Inc
|
79,856 | $2,242,356 | |
| 7 | AMGN |
Amgen Inc
|
5,229 | $1,839,823 | |
| 8 | AZN |
Astrazeneca PLC
|
6,722 | $1,325,712 |
All Filings in SCLX
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $6 | 1 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $12 | 1 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $19 | 1 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $5 | 1 | Shares | Sole | 2025-08-12 | |
| No filing history on record for this holder in this stock. | ||||||